Top 5 Stock Gains for September 2026: The S&P 500 Winners That Beat a Rough Month

Every month, we sit down with the closing numbers and ask one simple question: who actually made money for shareholders, and why? September usually gives us a short list. It has a reputation as the weakest month on the calendar, and seasonal data backs that up. A TrendSpider seasonality review puts September's historical win rate for one megacap at just 42%, with an average decline of 2.5%.

September 2026 was strange, though. The headline index looked calm. Underneath, it was a different story. I want to walk you through the five biggest S&P 500 gainers of the month, explain the catalysts in plain English, and share what we think matters before you chase any of them.

September 2026 at a Glance: A Calm Index Hiding a Rough Month

Here is the context that frames everything below. According to CNBC, the S&P 500 finished September only about 1% below its August all-time high, yet roughly three out of every four stocks in the index fell during the month. A handful of giants did the heavy lifting.

The broader market looked even weaker. StockTitan's monthly ranking of more than 4,300 U.S.-listed companies found that only 34% finished higher through late September, and the median stock lost 3.1%. Over that same stretch, the SPDR S&P 500 ETF (SPY) gained just 1.26%.

That is what analysts call narrow market breadth. When breadth is narrow, a small group of leaders carries the index while most stocks struggle. It is exactly why monthly leaderboards like this one are worth studying. They show you where the money is really flowing.

The team at Bespoke Investment Group summed up the month neatly:

"Technology was the place to be among September's biggest S&P 500 winners."

Tech accounted for 13 of the month's 20 best performers. But as you will see, our top five also includes a biotech, a fuel cell maker and a social media giant.

Quick Comparison: September's Top 5 S&P 500 Gainers

Rank	Company (Ticker)	September Gain	2026 YTD (approx.)	Main Catalyst
1	Everpure (P)	+40.70%	Nearly doubled	FY28 outlook, S&P 500 inclusion
2	Moderna (MRNA)	+37.2%	+553%	Cancer vaccine momentum
3	Intel (INTC)	+34.3%	+200% or more	AI server CPU demand
4	Bloom Energy (BE)	More than 30%	+200% or more	S&P 500 inclusion, AI data center power
5	Meta Platforms (META)	+26.70%	+9.86%	Muse AI assistant launch

Data: September and YTD figures from Bespoke and Stocktwits via TradingView. Everpure YTD from Yahoo Finance.

How We Built This List

We kept the method simple and transparent. We only looked at S&P 500 members, because thinly traded microcaps can post 200% monthly gains on almost no volume, and that tells you very little. StockTitan's all-market list, for example, was led by tiny names like Greenland Energy, which jumped roughly 299% in September. Interesting, but not useful for most investors.

We used month-end price returns reported by Bespoke and Stocktwits, then cross-checked each catalyst against company announcements and analyst notes. Ranks one through four come straight from those month-end tallies. For the fifth slot, we chose Meta, the largest company on Bespoke's top 20 list and the most important megacap story of the month.

Now, let's get into the winners.

1. Everpure (P): +40.70%

If you had told me in August that the former Pure Storage would top the S&P 500 in September, I would have been skeptical. Yet here we are. Stocktwits called it the month's surprise winner.

What happened. Everpure stacked three catalysts on top of each other in about four weeks:

Strong Q2 results (August 26). Revenue climbed 38% to $1.2 billion, and product revenue jumped 54%.
S&P 500 inclusion (September 21). The company replaced The Trade Desk in the index. That forced buying from every index fund that tracks the benchmark.
A blowout investor day (September 23). Management issued preliminary fiscal 2028 guidance of $7 billion to $7.3 billion in revenue and $1.7 billion to $1.9 billion in non-GAAP operating income.

That last number is the one that stunned Wall Street. According to Yahoo Finance, analysts polled by Visible Alpha had expected just $5.23 billion in revenue and $1.09 billion in operating income. The stock jumped nearly 18% the next day.

The expert view. Analysts rushed to raise targets. Citi lifted its price target to $160 from $130 and described the moment as an "inflection point." Bank of America moved its target to $180. Morgan Stanley argued the company could support a new "Rule of 60" baseline. (The Rule of 40 is a software benchmark where revenue growth plus profit margin should exceed 40%. Hitting 60 is elite territory.)

Our take. The growth story is real, but so is the price tag. Shaun Pruitt at Zacks pointed out that Everpure trades above 100 times forward earnings and 7 times forward sales. His conclusion was blunt:

"Investors may not need to chase the rally."

We agree. Everpure crushed fellow storage names SanDisk (+17.2%) and Western Digital (+1%) last month. That kind of gap often narrows.

2. Moderna (MRNA): +37.2%

Moderna is the comeback story of 2026, and September added another big chapter. The stock rose 37.2% for the month and finished up an astonishing 553% year to date, according to Bespoke.

What happened. The foundation was laid in August. Moderna and Merck reported a successful late-stage (Phase 3) trial of their personalized mRNA cancer vaccine in melanoma. Nemo reported that the stock soared around 177% in a single day on that news, one of the largest one-day moves for a major U.S. company in memory.

In September, the buying simply kept coming. On September 11, shares rose 8% to $147.37 with no company news at all. 24/7 Wall St. noted that peers BioNTech and Merck barely moved that day, which pointed to positioning, meaning who owns the stock and how, rather than fresh fundamentals.

Why it matters. A personalized cancer vaccine, technically called an individualized neoantigen therapy, is built from a patient's own tumor mutations. If it works at scale, it opens a market far bigger than COVID vaccines ever were.

Our take. We love the science. We are more cautious about the chart. A stock that can jump 177% in a day can also drop sharply on a single trial delay or FDA question. For most readers, I think a small position or a biotech ETF is a saner way to get exposure.

3. Intel (INTC): +34.3%

Intel's September is a lesson in patience. On September 1, the stock was sitting near $89, down about 31% from its June peak of $128, according to TIKR. Many traders had given up on it. Then it rallied 34.3% in a single month.

What happened. The driver was demand for central processing units (CPUs) inside AI servers. While graphics chips (GPUs) do most of the AI training work, every AI server still needs CPUs to manage data and run inference tasks. PrimeXBT reported that CEO Lip-Bu Tan said Intel can currently meet only about half of existing CPU demand. That is a supply problem most companies would love to have.

Intel has been spending to fix it. The company raised its 2026 capital expenditure plan above $20 billion and completed a $23 billion capital raise in August to fund new capacity. The stock posted a 12.14% single-day gain on September 21 and ended the month around $123.

The expert view. Wall Street is still split. As of September 1, Intel had 12 buy ratings, 2 outperform ratings, and 32 holds. That is a lot of fence-sitting for a stock up more than 200% this year.

Our take. Intel now trades around 84 times this year's earnings estimates and 62 times 2027 estimates. Compare that with Nvidia at roughly 28 times earnings. We see Intel as a high-beta bet that AI demand keeps accelerating. Beta measures how much a stock moves relative to the market, and Intel's is above 2. In plain terms, it can swing twice as hard as the S&P 500 in either direction.

4. Bloom Energy (BE): More Than 30%

Bloom Energy rounded out the four stocks that gained more than 30% in September, according to Bespoke. StockTitan's data showed BE up 35.14% through September 25, so the final tally landed somewhere in the mid-30s.

What happened. On September 4, S&P Dow Jones Indices announced that Bloom would join the S&P 500 on September 21, replacing Molson Coors. According to Finviz, Bloom became the first energy company added to the index since 2022.

The fundamentals backed it up. Bloom reported record Q2 revenue of $1.07 billion, up 166% year over year, with product revenue up 215%. The reason is simple: AI data centers need enormous amounts of power, fast. Bloom's solid oxide fuel cells generate electricity on site, which lets data centers avoid waiting years for a utility grid connection.

The expert view. UBS analyst Manav Gupta raised his price target to $325 from $300 and called the index inclusion a "significant positive catalyst," per Stocktwits. CEO KR Sridhar also highlighted how financial partner Brookfield expanded its commitment after watching Bloom deliver, telling TIKR that Brookfield "multiplied that backing by 500%."

Our take. Bloom climbed from about $206 to nearly $290 in less than a month. That is spectacular, but the stock now carries a price-to-earnings ratio near 337, according to Parameter. As TIKR noted, a miss or flat guidance at that multiple leaves little to cushion the fall. We would wait for the next earnings report before adding.

5. Meta Platforms (META): +26.70%

Meta is the most important name on this list for one reason: size. At roughly $1.9 trillion in market value, a 26.70% monthly gain adds hundreds of billions of dollars to the index. It is one of the giants CNBC credited with masking the weakness underneath.

What happened. On September 8, Meta launched Muse, a personal AI agent that can shop, plan trips, write emails and manage daily tasks. It offers free access plus paid tiers at $20 and $100 per month. According to Stocktwits, the stock was on pace for its best month since July 2013, at one point up about 36% for September before giving some back late in the month.

Muse reportedly hit number one among free apps in the U.S. Apple App Store within its first week. Meta also cleared a major legal overhang earlier, agreeing to pay up to $18 billion to resolve a social media addiction lawsuit.

The expert view. J.P. Morgan upgraded Meta to Buy and raised its target to $820 from $640, citing early Muse traction. Wells Fargo raised its target to $796.

Our take. Muse matters because it gives Meta a subscription revenue stream outside of advertising. The risk is spending. Capital expenditures are projected to reach $215 billion in 2028. Even after September's run, Meta was up only 9.86% for the year, the smallest YTD gain on Bespoke's top 20 list. That makes it, in our view, the least stretched name of these five.

Three Patterns We Noticed in September's Winners

Looking across the five, a few themes jumped out at us.

1. The S&P 500 inclusion effect is real. Two of our top four, Everpure and Bloom, joined the index on the same day. When a stock enters the S&P 500, passive funds must buy it regardless of price. Dutch outlet De Belegger cited research showing new index members gained an average of 16% in the year after joining. That historical edge is often front-loaded, though, so late buyers can miss it.

2. AI infrastructure keeps broadening. Last year, the AI trade meant Nvidia. In September 2026, it meant storage (Everpure), CPUs (Intel), on-site power (Bloom), and consumer AI apps (Meta). The money is spreading out across the whole supply chain.

3. Valuations are stretched. Everpure above 100x forward earnings, Intel at 84x, Bloom near 337x trailing. Momentum can last longer than anyone expects, but these multiples leave very little room for disappointment.

What We're Watching in October

October is earnings season, and that will test every one of these rallies. Here is our short checklist:

Everpure: Any update on hyperscaler deals that support the FY28 guidance.
Moderna: Regulatory timelines for the melanoma vaccine.
Intel: Progress on CPU supply and foundry customer announcements.
Bloom Energy: Whether Q3 revenue tracks consensus near $1.07 billion and guidance moves higher.
Meta: Paid Muse subscriber numbers and any capex revisions.

We also want to see breadth improve. A market where 75% of stocks fall in a month while the index holds near records is fragile. If leadership broadens, these gains are more likely to stick.

The Bottom Line

September 2026 rewarded investors who owned the right handful of names and punished almost everyone else. Everpure, Moderna, Intel, Bloom Energy and Meta each had a clear, specific catalyst. None of them rallied on hope alone.

Still, past performance is not a forecast. As NerdWallet reminds readers, predicting the next winners is a job even professionals haven't mastered. If you are tempted by any of these stocks, I would size positions small, check valuations carefully, and remember that a broad index fund already owns all five.

This article is for informational purposes only and is not financial advice. We do not hold positions in the stocks mentioned. Always do your own research or consult a licensed advisor before investing.